Ingrid Mayer
英格丽德·迈尔
MD, MSCI
Professor of Medicine, Director of Breast Cancer Research医学教授，乳腺癌研究主任
👥Biography 个人简介
Ingrid Mayer is a leading breast oncologist at Vanderbilt, with expertise in HER2-low disease, CDK4/6 inhibitor combinations with endocrine therapy, and early-stage breast cancer clinical trials. She has shaped treatment standards across HR+, HER2-low, and luminal subtypes.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
HER2-Low Breast Cancer Characterization and Treatment
Contributed to defining HER2-low as a clinically distinct entity and investigating targeted therapies including T-DXd and novel ADCs in this population.
CDK4/6 Inhibitors with Endocrine Therapy
Led trials integrating CDK4/6 inhibitors into early and metastatic HR+ breast cancer regimens, optimizing sequence and combination strategies.
Representative Works 代表性著作
Trastuzumab deruxtecan in HER2-low breast cancer: clinical and translational insights
Journal of Clinical Oncology (2023)
Provided key analyses of T-DXd activity in HER2-low disease, characterizing predictive biomarkers and informing patient selection.
Phase II study of neoadjuvant CDK4/6 inhibitor plus letrozole in early HR+ breast cancer
Annals of Oncology (2020)
Demonstrated biological activity of CDK4/6 inhibition with endocrine therapy in early-stage HR+ breast cancer neoadjuvant setting.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
关注 英格丽德·迈尔 的研究动态
Follow Ingrid Mayer's research updates
留下邮箱，当我们发布与 Ingrid Mayer（Vanderbilt-Ingram Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment